Journal article

Safety and Effectiveness of a Next-Generation Contact Force Catheter: Results of the TactiSense Trial.

Monica Y Lo, Prashanthan Sanders, Phillipp Sommer, Jonathan M Kalman, Usman R Siddiqui, Sri Sundaram, Christopher Piorkowski, Nicholas Olson, Steven M Madej, Douglas N Gibson

JACC Clin Electrophysiol | Published : 2021

Abstract

OBJECTIVES: The objective of this clinical trial was to evaluate the safety and effectiveness of the TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) (Abbott, Abbott Park, Illinois) for the treatment of drug-refractory, symptomatic paroxysmal atrial fibrillation (PAF). BACKGROUND: Catheter ablation of atrial fibrillation (AF) is an established therapy for the treatment of PAF. Ablation technology is evolving with the primary goals of improving efficacy and safety of the procedure. METHODS: This was a multicenter single-arm trial evaluating a novel ablation catheter for the treatment of PAF. A total of 156 subjects were enrolled at 19 sites in the United States, Europe..

View full abstract